News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,773 Results
Type
Article (14900)
Company Profile (300)
Press Release (266567)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79904)
Career Advice (162)
Deals (13354)
Drug Delivery (39)
Drug Development (50699)
Employer Resources (31)
FDA (5861)
Job Trends (5168)
News (145186)
Policy (10081)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (921)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21765)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (244)
Approvals (6055)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3128)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43667)
Collaboration (1148)
Company closure (2)
Compensation (592)
Complete response letters (39)
COVID-19 (1101)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4319)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1433)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31698)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51697)
Executive appointments (621)
FDA (7608)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (504)
Government (1149)
Grass and pollen (3)
Guidances (166)
Healthcare (6616)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1205)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7353)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1402)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2665)
Medtech (2674)
Mergers & acquisitions (6624)
Metabolic disorders (725)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2036)
Non-profit (866)
Now hiring (30)
Obesity (330)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26655)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15475)
Phase 2 (20287)
Phase 3 (12821)
Pipeline (3241)
Policy (90)
Postmarket research (853)
Preclinical (6536)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1448)
Recruiting (12)
Regulatory (9899)
Reports (19)
Research institute (972)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2007)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Last 7 days (344)
Last 30 days (1117)
Last 365 days (17806)
2026 (1653)
2025 (18107)
2024 (20544)
2023 (22417)
2022 (26836)
2021 (27849)
2020 (23395)
2019 (16241)
2018 (11760)
2017 (13761)
2016 (11842)
2015 (14359)
2014 (10414)
2013 (7484)
2012 (7533)
2011 (7615)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18253)
Australia (3115)
California (7083)
Canada (1836)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39158)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (396)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5578)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1760)
North Carolina (825)
North Dakota (6)
Northern California (3481)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2807)
Tennessee (40)
Texas (905)
United States (23332)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,773 Results for "lyra therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lyra Therapeutics Provides Corporate Update
January 12, 2026
·
4 min read
Press Releases
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
·
9 min read
Press Releases
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
October 6, 2025
·
7 min read
Press Releases
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 12, 2025
·
13 min read
Business
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by implementing a layoff of approximately 75% of its workforce, in addition to other cost-cutting measures.
May 21, 2024
·
8 min read
Press Releases
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 7, 2025
·
10 min read
Press Releases
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
June 27, 2025
·
6 min read
Genetown
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 26, 2024
Lyra Therapeutics, Inc. announced that it has granted non-qualified stock options to purchase a total of 78,400 shares of Lyra Therapeutics common stock to 16 new non-executive employees as an inducement material to their acceptance of employment with Lyra Therapeutics.
April 26, 2024
·
2 min read
Drug Development
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced topline results from the Company’s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis (CRS).
May 6, 2024
·
8 min read
Business
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
March 21, 2024
·
12 min read
1 of 28,178
Next
